Journal article icon

Journal article

Lymphoma risk and overall safety profile of Adalimumab in patients with Crohn's disease with up to 6 years of follow-up in the pyramid

Abstract:
OBJECTIVES Real-world, prospective, long-term studies in Crohn’s disease (CD) characterizing adalimumab safety data and lymphoma risk were lacking. We present the final results from the PYRAMID registry, which was designed to rule out a doubling of lymphoma risk in adalimumab-treated patients with CD. Methods Patients with moderately to severely active CD newly prescribed or currently receiving adalimumab according to local product labels were followed for u... Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1038/s41395-018-0098-4

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
NDM Experimental Medicine
Oxford college:
Green Templeton College
Role:
Author
Expand authors...
Publisher:
Springer Nature Publisher's website
Journal:
American Journal of Gastroenterology Journal website
Volume:
882
Issue:
113
Pages:
872–882
Publication date:
2018-06-05
Acceptance date:
2018-04-04
DOI:
EISSN:
1572-0241
ISSN:
0002-9270
Source identifiers:
894292
Pubs id:
pubs:894292
UUID:
uuid:451f0710-f573-4075-834f-0ecf270aea4d
Local pid:
pubs:894292
Deposit date:
2018-08-06

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP